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Abstract
Rationale
Nitric oxide synthase (NOS) is a biomarker/target in sepsis. NOS activity is driven by amino
acids, which cycle to regulate the substrate L-arginine in parallel with cycles which regulate
the endogenous inhibitors ADMA and L-NMMA. The relationship between amines and the
consequence of plasma changes on iNOS activity in early sepsis is not known.
Objective
Our objective was to apply a metabolomics approach to determine the influence of sepsis
on a full array of amines and what consequence these changes may have on predicted
iNOS activity.
Methods and measurements
34 amino acids were measured using ultra purification mass spectrometry in the plasma of
septic patients (n = 38) taken at the time of diagnosis and 24–72 hours post diagnosis and of
healthy volunteers (n = 21). L-arginine and methylarginines were measured using liquid-
chromatography mass spectrometry and ELISA. A top down approach was also taken to
examine the most changed metabolic pathways by Ingenuity Pathway Analysis. The iNOS
supporting capacity of plasma was determined using a mouse macrophage cell-based
bioassay.
Main results
Of all the amines measured 22, including L-arginine and ADMA, displayed significant differ-
ences in samples from patients with sepsis. The functional consequence of increased
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ADMA and decreased L-arginine in context of all cumulative metabolic changes in plasma
resulted in reduced iNOS supporting activity associated with sepsis.
Conclusions
In early sepsis profound changes in amine levels were defined by dominant changes in the
iNOS canonical pathway resulting in functionally meaningful changes in the ability of plasma
to regulate iNOS activity ex vivo.
Introduction
Sepsis kills as many as 40% of patients and there are no drugs available that reduce mortality.
The prevailing view is that vascular dysfunction and ultimately organ failure in sepsis is driven
by excessive amounts of nitric oxide (NO) formed by the enzyme inducible nitric oxide syn-
thase (iNOS). iNOS is expressed in leukocytes in response to invading pathogens as an essen-
tial part of the innate immune response. It is thought however, that in sepsis iNOS is also
expressed in vascular [1–3] and cardiac cells leading to vasoplegia [1–3] and reduced cardiac
function [4]. The amount of NO formed by iNOS is controlled by (i) levels of the substrate,
L-arginine and (ii) levels of the substrate inhibitors asymmetric dimethylarginine (ADMA)
and monomethylarginine (L-NMMA)[5]. ADMA and L-NMMA, together with symmetric
dimethylarginine (SDMA) are known as ‘methylarginines’. Moreover, there are inherent com-
plexities in the iNOS system because L-arginine cycles with other amino acids including L-cit-
rulline, L-ornithine and L-glutamine [6]. This point is particularly relevant since levels of most
amino acids are known to be altered in sepsis [7].
iNOS was first identified as a therapeutic target for sepsis in the early 1990s in a clinical case
study that showed blocking NOS with L-NMMA reversed hypotension in two terminally ill
patients with septic shock [8]. This, together with a substantial body of preclinical work, led to
a large multiple-center clinical trial to assess the effects of L-NMMA on mortality. However,
L-NMMA increased mortality and the trial was stopped prematurely [9]. It is thought that
exogenous L-NMMA failed to deliver the promised therapeutic benefits because it acts in a
non-discriminatory manner leading to ‘over correction’ of the NO pathway leaving the heart
[10, 11] and other organs unprotected from the surge in endogenous constrictor hormones
released during sepsis. As an alternative approach to administration of exogenous inhibitors it
has been suggested that manipulating levels of endogenous levels of L-arginine, other amino
acids and/or methylarginines could be a safer strategy to target iNOS activity in sepsis [12].
Since L-NMMA and ADMA are substrate inhibitors levels of L-arginine dictate their effect
on iNOS. L-arginine is a semi-essential amino acid. This means that in healthy adults sufficient
levels are generated endogenously [13–15], whereas in infants or in people with severe disease,
including those with sepsis, L-arginine is not replete and must be supplemented from external
sources [16]. Sepsis is associated with increased levels of ADMA [17, 18] and reduced levels of
L-arginine [19, 20]. However, the precise relationship between methylarginines, arginine and
other amino acids in the NO cycle in sepsis is not known. Moreover, the functional signifi-
cance of sepsis related changes in plasma on iNOS activity and how this might be linked to
arginine and ADMA has not yet been addressed. Thus, in the current study we have adopted a
metabolomics approach to systematically measure a comprehensive array of amines, including
amino acids and methylarginines in the plasma of a well-defined cohort of patients with sepsis.
We have done this in order to determine the actual and relative importance of changes in
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NOS canonical pathways in sepsis to ultimately translate our findings to a personalised
medicine approach for nutritional support in sepsis. Moreover, in order to interpret and bio-
logically validate our findings, we developed a cell-based bioassay to test the functional signifi-
cance of changes in plasma composition in sepsis on iNOS activity.
Methodology
Cell culture
RAW 264.7 mouse macrophages (ATCC, USA), were cultured using Dulbecco’s Modified
Eagle’s Medium (Sigma-Aldrich, UK) supplemented with 2mM L-glutamine (Sigma Aldrich,
UK), nonessential amino acids (Invitrogen, UK) and penicillin-streptomycin (Sigma Aldrich,
UK) at 5% CO2 and 37˚C. At confluence, cells were scraped and spun at 400 relative centrifu-
gal force for 5 minutes. 10% filtered foetal bovine serum (LabTech, UK) was included only
when culturing.
Clinical study
Plasma samples were collected into anticoagulant heparin vacutainers from healthy volunteers
(n = 21; 11M and 10F; 32.5 ± 6.7years) or sepsis patients (n = 38) at diagnosis (0) and 24 hours
and 72 hours post diagnosis in the intensive care unit (ICU) at Royal Brompton Hospital, UK.
Sepsis patient demographics are shown in Table 1. This study was approved by a Research
Table 1. Patient demographics. Basic clinical information of patients with sepsis involved in the study is
shown. Abbreviations for clinical assessments are APACHE II = Acute Physiology and Chronic Health Evalua-
tion and SOFA = Sequential Organ Failure Assessment score. Data are shown as individual numbers for
n = 38 for patients with sepsis.
Category Number of patients (number/ mean)
Gender-M/F M (22) and F (16)
Age (years) 60 ± 16.7
Body mass index (Kg/m2) 26.3 ± 0.7
Length of stay in ICU (days) 39.0 ± 5.4
Liver function tests Good/normal (20)
Moderate (8), Moderate dysfunction/poor (6)
Severe dysfunction (3)
Right ventricular function Good/normal (5)





APACHE II: 18.7 ± 1.0
SOFA1: 9.2 ± 0.4
SOFA2: 9.0 ± 0.5
SOFA3: 8.5 ± 0.6
Diagnoses (more than one may be
applicable per patient)
Sepsis/systemic inflammatory response syndrome/ multiple
organ dysfunction (38)
Pneumonia/acute respiratory distress syndrome (20)
Endocarditis (1)
Cardiac dysfunction (7)
Acute renal failure (15)
Co-morbidities Ischaemic heart disease (13)
Hypertension (10)
Non-insulin dependent diabetes mellitus (5)
Asthma/chronic obstructive pulmonary disease (3)
Peripheral vascular disease (4)
Mortality (%) 29.0 (6M and 5F)
https://doi.org/10.1371/journal.pone.0183025.t001
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Ethics Committee at Royal Brompton Hospital (RBH 01–152), Imperial College London (RBH
00–062). All volunteers gave written informed consent before entering the study.
Measurements of iNOS supporting capacity of clinical plasma samples
Neat (100%) plasma was added directly to RAW 264.7 (1x105) cells in the presence of LPS
(1μg/ml) in a 96 well plate for 24 hours then used for nitrite measurements.
Nitrite measurements
Samples were measured at 570nm by spectrophotometer (Infinite1F50; Tecan, Switzerland)
using the Griess assay and a sodium nitrite standard curve (0-1mM).
LC-MS/MS measurements
Samples were analysed as described previously [21] using an Agilent 6400 series triple quadru-
ple liquid-chromatography tandem mass-spectrometry (LC-MS/MS) and mobile phase (0.1%
formic acid, 1% acetonitrile). Read outs were from MassHunter Qualitative Analysis software
(Agilent Technologies; Santa Clara, CA, USA) and concentrations from standard curves.
ADMA and L-arginine ELISA
ADMA and L-arginine levels in clinical samples were determined using an enzyme immuno-
assay (DLD Diagnostika, Germany), as described previously [22].
Ultra high performance liquid chromatography—Mass spectrometry
(UHPLC-MS/MS) analysis of amines
Proteins were removed from plasma samples by precipitation with isopropanol (0.1% formic
acid). Amines were measured using a HSS T3 UHPLC column system (Waters, Milford,
MA, USA) connected to a Xevo TQ-S tandem quadrupole mass spectrometer (Waters, Wilm-
slow, UK) [23, 24]. Isotopically labelled standards (10μg/ml) and calibration curves (Sigma;
1–400μM) were used for quantification. MS/MS detection was via electrospray ionisation
(ESI) in positive ion mode using multiple reaction monitoring (MRM) transitions. Analyte
levels (reported as μM values) were calculated as a ratio of analyte peak area against appropri-
ate internal standards, after 7.5 minute run.
Heat map construction
UHPLC-MS/MS amine measurements from patients with sepsis were normalised to those
from healthy patients and fold changes shown by pictographic scale representing a five-fold
increase (red) or decrease (green).
Ingenuity Pathway Analysis (IPA)
A ratio of healthy donor and patient amine measurements were analysed (IPA, Qiagen Red-
wood City, www.qiagen.com/ingenuity). The association between analytes and canonical path-
ways was tested by the Benjamini-Hocberg test with a false discovery rate of 0.05.
Statistical analysis
Data are mean ± S.E.M for n donors/ experiments. Unless stated otherwise, all statistical tests
were performed using GraphPad Prism v5 (GraphPad Inc., UK) and defined in figure legends.
Statistical significance was noted when p<0.05.
Metabolomic amine profiling in sepsis
PLOS ONE | https://doi.org/10.1371/journal.pone.0183025 August 15, 2017 4 / 11
Fig 1. Targeted metabolic profiling of amines and methylarginines in human plasma from healthy donors
and patients with sepsis. Amine and methylarginine levels were measured using (A) UHPLC-MS/MS, LC-MS/MS
and/or ELISA in the plasma of healthy donors and patients with sepsis at diagnosis (0 hours), 24 hours and 72 hours
post diagnosis. Comparisons between levels of L-arginine from (B) UHPLC-MS/MS, LC-MS/MS and ELISA and (C)
ADMA from LC-MS/MS and ELISA are shown at diagnosis (0 hours), 24 hours and 72 hours, post diagnosis. (D)
Canonical pathways extracted from IPA software were based on an input of read outs comparing plasma levels of
amines in healthy donors and patients with sepsis as a ratio. Data are ± SEM for n = 21 healthy donors and n = 38
patients with sepsis. Data was analysed by one-way ANOVA with Dunnett’s post-hoc test and Benjamini-Hochberg
test with a false discovery rate of 0.05; *p<0.05.
https://doi.org/10.1371/journal.pone.0183025.g001
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Results and discussion
Three separate analytical techniques were used to determine the levels of amines in plasma
from patients with sepsis. Firstly, an optimised UHPLC-MS/MS system was used to quantify
38 amines including L-arginine. Of those 38 analytes, 34 were measurable in human plasma
and 21, including L-arginine, displayed significant differences in samples from patients with
sepsis (Fig 1A; S1 Table). Secondly, to validate observations with L-arginine and to include
the measurement of ADMA and SDMA, a second LCMS/MS approach was used (Fig 1B; S1
Table). Finally, for further validation measurements of L-arginine and ADMA were performed
using ELISA (Fig 1C). It is commonly held that sepsis is a state of arginine deficiency, although
a recent study found that arginine was increased in early sepsis [25]. In line with the other
studies, here we found that L-arginine levels were lower in plasma of patients with sepsis
within the first 24 hours after diagnosis but increased in the subsequent 48–72 hours. In our
samples L-arginine levels were remarkably similar and showed identical trends when mea-
sured using each of the three analytical approaches (Fig 1). By contrast to L-arginine, ADMA
levels increased at the point of diagnosis of sepsis and continued to rise at 24 and 72 hours (Fig
1). Again, as with L-arginine, whilst the absolute concentrations recorded were different, the
pattern of change in ADMA was consistent when measured using LCMS/MS or ELISA. The
reduced L-arginine and increased ADMA translated to an increase in ADMA:L-arginine ratio
in plasma of patients with sepsis, and driven by increased ADMA, were elevated throughout
the entire period of collection (Fig 2).
Fig 2. ADMA:L-arginine ratio in healthy donors vs patients with sepsis. ADMA and L-arginine were measured from
plasma of healthy donors and patients with sepsis at diagnosis (0 hours), 24 and 72 hours post diagnosis using ELISA.
Data are ± SEM for n = 21 healthy donors and n = 38 patients with sepsis. Data was analysed by one-way ANOVA with
Dunnett’s post-hoc test. *p<0.05.
https://doi.org/10.1371/journal.pone.0183025.g002
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Pathway analysis of the total data set revealed significant changes in a range of canonical
pathways extracted from IPA software (Fig 1D; S1 Fig). All three NOS pathways were signifi-
cantly changed by sepsis and of all pathways, iNOS was found to be the most down regulated
(S1 Fig). This result is in line with increased ADMA, reduced levels of L-arginine and reduced
amino acids involved in the de novo synthesis of L-arginine such as L-glutamine and L-citrul-
line [13–15]. Together these findings strongly suggest that the ability of plasma from patients
with sepsis to support optimal iNOS activity could be reduced and that in this setting strate-
gies, such as blocking DDAH [12], to increase ADMA would indeed have functional conse-
quences. To test this idea, we used a well-characterised mouse macrophage bioassay where
iNOS activity is induced by LPS.
Fig 3. iNOS activity in LPS-activated mouse macrophages treated in culture media. iNOS activity in macrophages was
measured in cells cultured in the presence of (A,B) 50μM or (C,D) 80μM L-arginine. Data are ± SEM for n = 4–6. Data was
analysed by (A,C) paired t-test and (B,D) one-way ANOVA with Dunnett’s post-hoc test. *p<0.05.
https://doi.org/10.1371/journal.pone.0183025.g003
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When mouse macrophages are grown in regular culture media, which contains excess L-
arginine (400μM), LPS induces concentration dependent increases in iNOS activity after 24
hours (S2A Fig). Under these conditions relatively high levels of ADMA are required to inhibit
nitrite formation (S2B Fig). However, levels of L-arginine in human plasma are very much
lower than those contained in regular culture media and, within the ranges we detected in this
study, are rate limiting for iNOS activity (S2C Fig). In line with this we found higher levels of
nitrite in media from LPS stimulated macrophages grown in media containing 80μM (eg
healthy) than 50μM (e.g sepsis) L-arginine (Fig 3A and Fig 3C). Under these conditions the
levels of ADMA present in plasma from patients with sepsis were sufficient to inhibit iNOS
Fig 4. iNOS activity in LPS-activated mouse macrophages treated in plasma from healthy donors and patients with sepsis.
(A) iNOS activity in plasma from healthy vs sepsis patients at 0, 24 and 72 hours. Correlations in ADMA:L-arginine ratio with iNOS
activity at (B) 0–24 hours and (C) 24–72 hours post diagnosis. Data are mean ± SEM for n = 21 healthy donors and n = 38 patients with
sepsis. Data was analysed by (A) Kruskal-Wallis one-way ANOVA with Dunn’s post-hoc test and (B-C) linear regression. *p<0.05
when compared to healthy.
https://doi.org/10.1371/journal.pone.0183025.g004
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activity in the presence of 50μM (Fig 3B), but not in 80μM L-arginine (Fig 3D). These findings
suggest that, assuming no other biological confounders were present; plasma from patients
diagnosed with sepsis would have a reduced capacity to support iNOS activity. However, as
>20 amino acids and amines were altered in the plasma of patients with sepsis, there may be
other metabolic changes which overwhelm the effect of changed ADMA:L-arginine ratio on
iNOS activity. To test this directly, plasma was added to LPS activated macrophages and iNOS
activity measured. As predicted from the ADMA:L-arginine ratio, obtained from plasma of
patients with sepsis, macrophages released lower levels of NO than those cultured in the pres-
ence of plasma from healthy control donors. This effect was seen in plasma taken from patients
with sepsis at diagnosis and after 24hours but was lost in plasma from patients at 48–72 hours
after sepsis had been diagnosed (Fig 4A). These findings were paralleled by a positive correla-
tion between ADMA:L-arginine ratios and iNOS activity in cells within the first 24 hours
(Fig 4B) but not after 24–72 hours (Fig 4C). These findings illustrate that in sepsis there is a
global reduction in ‘iNOS supporting activity’ within the plasma. If this extrapolates to con-
ditions within the body we would expect the entire NO pathway, whilst still active, to be com-
promised. The implications for this include (i) reduced endothelial derived NO which is
consistent with reduced blood flow in some organs and (ii) reduced NO from immune cells
attributing to immune suppression. Taken together these points support the idea of L-arginine
supplementation in sepsis. However, iNOS is also expressed in vascular smooth muscle cells in
sepsis where its activity is thought to underpin vasoplegia and associated pressure resistant
hypotension. In this scenario L-arginine supplementation would enhance vascular dysfunction
and could contribute to shock. Thus, the significance of a reduced capacity to support NO at
the level of ADMA:L-arginine needs to be carefully considered in context of individual pa-
tients and requires further investigation before any impact on clinical management can be
made.
In summary, there have been several studies in the literature showing that sepsis is associ-
ated with an increased ADMA:L-arginine ratio. However, ours is the first report that translates
and validates observational measurements of ADMA and L-arginine to show meaningful
biological consequences in sepsis conditions. This work provides essential proof of concept
evidence for the idea that targeted metabolic profiling of amine levels in patients with sepsis
can identify temporal nutritional deficiencies and to the notion that enhancing endogenous
levels of ADMA, will impact on iNOS activity despite the complex changes in plasma constitu-
ents seen in sepsis. How this information may be harnessed to develop patient specific, person-
alised medicine, interventions remains the subject of investigation.
Supporting information
S1 Fig. List of the top 20 canonical pathways altered in plasma of patients with sepsis. A
total of 134 pathways, of which 77 were significantly altered were determined (top 20 shown).
Data are shown as the percentage and number of pathway molecules down or upregulated.
Ratios were generated for each of 34 analytes using data for n = 21 healthy donors and n = 38
patients with sepsis. Data was analysed by Benjamini-Hochberg test with a false discovery rate
of 0.05 applied. Individual P values are shown in brackets.
(TIF)
S2 Fig. Effect of (A) LPS and (B) ADMA in control media (contains400μM arginine)
and (C) L-arginine in arginine free media on iNOS activity in mouse macrophages. iNOS
activity was determined from nitrite concentrations in conditioned media after 24 hours. LPS
was added at 1μg/ml in panels (B) and (C). Data are mean ± SEM and n = 3 individual experi-
ments. Data was analysed by one-way ANOVA followed by Dunnett’s post-hoc test compared
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to control. p<0.05.
(TIF)
S1 Table. List of amines measured in human plasma using UHPLC-MS/MS, LC-MS/MS
and/or ELISA. Data are mean ± SEM for n = 21 healthy donors and n = 38 patients with sep-
sis. Data was analysed by either one-way ANOVA with Dunnett’s post-hoc test or, where
appropriate, Kruskal-Wallis one-way ANOVA with Dunn’s post-hoc test. p<0.05 when com-
pared to healthy controls.
(TIF)
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